دورية أكاديمية
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
| العنوان: | Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis? |
|---|---|
| المؤلفون: | Shafa A; Mayo Clinic, Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Rochester, MN, United States of America., Watkins AB; Mayo Clinic, Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Rochester, MN, United States of America., McGree ME; Mayo Clinic, Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Rochester, MN, United States of America., Weroha SJ; Mayo Clinic, Department of Oncology, Rochester, MN, United States of America., Wahner Hendrickson AE; Mayo Clinic, Department of Oncology, Rochester, MN, United States of America., Block MS; Mayo Clinic, Department of Oncology, Rochester, MN, United States of America., Langstraat CL; Mayo Clinic, Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Rochester, MN, United States of America; Mayo Clinic, Department of Oncology, Rochester, MN, United States of America., McBane RD 2nd; Mayo Clinic, Department of Cardiovascular Disease, Rochester, MN, United States of America., Bakkum-Gamez JN; Mayo Clinic, Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Rochester, MN, United States of America., Kumar A; Mayo Clinic, Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Rochester, MN, United States of America. Electronic address: kumar.amanika@mayo.edu. |
| المصدر: | Gynecologic oncology [Gynecol Oncol] 2023 Sep; Vol. 176, pp. 36-42. Date of Electronic Publication: 2023 Jul 11. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, Academic Press. |
| مواضيع طبية MeSH: | Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/surgery , Ovarian Neoplasms*/pathology , Venous Thromboembolism*/epidemiology , Venous Thromboembolism*/etiology , Venous Thromboembolism*/prevention & control, Humans ; Female ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/surgery ; Carcinoma, Ovarian Epithelial/complications ; Neoadjuvant Therapy/adverse effects ; Anticoagulants/adverse effects ; Incidence ; Retrospective Studies |
| مستخلص: | Objectives: Our objectives were to determine the incidence, timing, and risk factors for venous thromboembolisms (VTEs) in patients with advanced stage epithelial ovarian cancer (EOC) who received neoadjuvant chemotherapy (NACT). We explored the utilization of direct-acting oral anticoagulants (DOACs) for VTE treatment. Methods: This retrospective cohort study included patients with advanced stage EOC receiving NACT followed by interval cytoreductive surgery (ICS) at a single institution. Risk factors were compared between patients with versus without VTE between EOC diagnosis and 180 days after ICS. Bleeding complications were compared between patient who received a DOAC versus non-DOAC. Results: VTE cases occurred amongst 33 of the 154 (21.4%) patients with 4 (2.6%) concurrent with EOC diagnosis, 9 (5.8%) between EOC diagnosis and NACT start, 13 (8.4%) between NACT start and ICS, and 7 (4.5%) within 180 days after ICS. There were no statistically significant differences in risk factors assessed (age, body mass index, functional status, histology, Khorana score, and smoking history) between patients with versus without VTE. Eleven patients (33.3%) received a DOAC for VTE treatment. There were no significant differences in number of intraoperative blood transfusions (p = 0.38), blood loss (p = 0.95), or bleeding complications (p = 0.53) between patients treated with a DOAC versus a non-DOAC. Conclusion: There is a high incidence of VTE events (21.4%) in patients with advanced stage EOC undergoing NACT. Two-thirds of the VTEs may have been prevented with thromboprophylaxis as they occurred between EOC diagnosis and ICS. These data support consideration of thromboprophylaxis in all patients with advanced stage EOC undergoing NACT. (Copyright © 2023 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Direct-acting oral anticoagulation; Neoadjuvant chemotherapy; Ovarian cancer; Thromboprophylaxis; Venous thromboembolism |
| المشرفين على المادة: | 0 (Anticoagulants) |
| تواريخ الأحداث: | Date Created: 20230713 Date Completed: 20230904 Latest Revision: 20230913 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.ygyno.2023.06.577 |
| PMID: | 37442024 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1095-6859 |
|---|---|
| DOI: | 10.1016/j.ygyno.2023.06.577 |